Cargando…

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus

OBJECTIVES: We investigated the cell adhesion molecules (CAMs) Vascular CAM 1 (VCAM-1) and Activated Leucocyte CAM (ALCAM) as urinary biomarkers in SLE patients with and without renal involvement. METHODS: Female SLE patients (n = 111) and non-SLE population-based controls (n = 99) were enrolled. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodis, Ioannis, Gokaraju, Sirisha, Zickert, Agneta, Vanarsa, Kamala, Zhang, Ting, Habazi, Deena, Botto, João, Serdoura Alves, Clara, Giannopoulos, Panagiotis, Larsson, Anders, Svenungsson, Elisabet, Gunnarsson, Iva, Mohan, Chandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449816/ https://www.ncbi.nlm.nih.gov/pubmed/31722419 http://dx.doi.org/10.1093/rheumatology/kez528

Ejemplares similares

Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
por: Soliman, Samar A., et al.
Publicado: (2022)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up
por: Gerhardsson, Jakob, et al.
Publicado: (2015)

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study
por: Karlsson, Linnea, et al.
Publicado: (2023)

Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study
por: Samuelsson, Isak, et al.
Publicado: (2021)

Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations
por: Mobarrez, Fariborz, et al.
Publicado: (2016)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
por: Oke, Vilija, et al.
Publicado: (2019)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer’s disease
por: Chen, Jian, et al.
Publicado: (2023)

Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus
por: Faustini, Francesca, et al.
Publicado: (2022)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis
por: Singh, Sandeep, et al.
Publicado: (2012)

Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE
por: Elbagir, Sahwa, et al.
Publicado: (2022)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2019)

Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus
por: Jönsen, Andreas, et al.
Publicado: (2011)

Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study
por: Gustafsson, Johanna T, et al.
Publicado: (2012)

Factors associated with self-reported capacity to walk, jog and run in individuals with systemic lupus erythematosus
por: KINIKLI, Gizem İrem, et al.
Publicado: (2020)

Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis
por: Hardt, Uta, et al.
Publicado: (2018)

The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses
por: Chalmers, Samantha A., et al.
Publicado: (2022)

Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus
por: Torell, Agnes, et al.
Publicado: (2023)

Excess atherosclerosis in systemic lupus erythematosus,—A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls
por: Gustafsson, Johanna T., et al.
Publicado: (2017)

Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus
por: Svenungsson, Elisabet, et al.
Publicado: (2020)

Role of early repeated renal biopsies in lupus nephritis
por: Zickert, A, et al.
Publicado: (2014)

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
por: Sjöwall, Christopher, et al.
Publicado: (2009)

Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA‐DRB1 Genotype Associations and Immunological and Clinical Manifestations
por: Diaz‐Gallo, Lina‐Marcela, et al.
Publicado: (2021)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
por: Bolin, Karin, et al.
Publicado: (2013)

Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis
por: Zickert, Agneta, et al.
Publicado: (2023)

Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study
por: Gustafsson, Johanna, et al.
Publicado: (2009)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE
por: Elbagir, Sahwa, et al.
Publicado: (2021)

A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM
por: Lei, Rongwei, et al.
Publicado: (2022)

A Research Study of the Association between Maternal Microchimerism and Systemic Lupus Erythematosus in Adults: A Comparison between Patients and Healthy Controls Based on Single-Nucleotide Polymorphism Using Quantitative Real-Time PCR
por: Kanold, Anna Maria Jonsson, et al.
Publicado: (2013)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e9dr75525cvoml5pp93otd083t